Because UM-164 can alter c-Src localization in triple negative breast cancer (TNBC) cells and displays anti-TNBC cell proliferative activity, UM-164 is a promising lead compound for the treatment of TNBC [28]. Here, SRC is linked to triple-negative breast carcinoma.